logo
Plus   Neg
Share
Email

Seattle Genetics Reports Positive Results From HER2CLIMB Trial Of TUKYSA

Seattle Genetics, Inc. (SGEN) reported positive results from exploratory analyses of intracranial efficacy, including survival, in patients with HER2-positive metastatic breast cancer who had stable or active brain metastases in the HER2CLIMB pivotal trial
of TUKYSA. TUKYSA in combination with trastuzumab and capecitabine was approved by the FDA in April for adult patients with advanced unresectable or metastatic HER2-positive breast cancer.

"These additional analyses, together with the primary analysis of HER2CLIMB, show TUKYSA is active for patients with and without disease that has spread to the brain," said Roger Dansey, Chief Medical Officer of Seattle Genetics.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT